GenePOC Announces FDA Clearance for Revogene(TM) Instrument and its GBS LB Test

GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument QUÉBEC CITY and LAUSANNE, Switzerlan... Diagnostics, FDA GenePOC, revogene, GBS LB, antepartum, Group B Streptococcus

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042595

Source: HSMN NewsFeed - June 1, 2017 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Group B Streptococcus | Pharmaceuticals